Envestnet Asset Management Inc. Acquires 141,601 Shares of DexCom, Inc. $DXCM

Envestnet Asset Management Inc. lifted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 18.5% in the third quarter, Holdings Channel reports. The fund owned 906,872 shares of the medical device company’s stock after purchasing an additional 141,601 shares during the quarter. Envestnet Asset Management Inc.’s holdings in DexCom were worth $61,023,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DXCM. Andra AP fonden bought a new stake in shares of DexCom in the 2nd quarter valued at approximately $26,000. Twin Peaks Wealth Advisors LLC purchased a new stake in DexCom during the 2nd quarter valued at $26,000. SJS Investment Consulting Inc. lifted its position in DexCom by 4,800.0% in the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after buying an additional 384 shares during the last quarter. Financial Consulate Inc. bought a new stake in DexCom in the third quarter worth $29,000. Finally, Sound Income Strategies LLC boosted its stake in DexCom by 83.8% during the third quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock worth $43,000 after buying an additional 285 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on DXCM. Sanford C. Bernstein reissued an “outperform” rating and issued a $86.00 target price (up previously from $84.00) on shares of DexCom in a research note on Friday, January 9th. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 16th. BTIG Research decreased their price objective on shares of DexCom from $109.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, October 31st. Barclays lowered DexCom from an “equal weight” rating to an “underweight” rating and dropped their target price for the company from $80.00 to $71.00 in a research report on Monday, January 12th. Finally, Citigroup reiterated a “buy” rating and issued a $77.00 price target (up from $75.00) on shares of DexCom in a report on Thursday, December 11th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $85.00.

DexCom Stock Up 0.3%

Shares of NASDAQ DXCM opened at $70.16 on Tuesday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $93.25. The firm has a market capitalization of $27.36 billion, a price-to-earnings ratio of 38.98, a PEG ratio of 1.25 and a beta of 1.49. The stock has a 50 day moving average price of $68.80 and a 200 day moving average price of $70.07. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56.

Insider Buying and Selling at DexCom

In other news, Director Richard Alexander Collins sold 2,906 shares of the stock in a transaction on Friday, November 14th. The stock was sold at an average price of $59.05, for a total transaction of $171,599.30. Following the transaction, the director owned 35,088 shares of the company’s stock, valued at approximately $2,071,946.40. This represents a 7.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the transaction, the director owned 27,031 shares in the company, valued at approximately $1,569,690.17. This represents a 3.61% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.32% of the stock is currently owned by corporate insiders.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.